Financebotresearch desk研究台

ZTS › analyze

ZTS · Analyze

WATCH Healthcare

🔴 POST-PRINT REVISION — 2026-08-06. Conviction 6.5 → 5.5. Read §9 first.

Zoetis reported Q2 on 2026-08-06 and cut FY2026 guidance for the second time. Adjusted EPS guidance went $6.85–7.00 → $6.15–6.25, which turns the steelman's central pillar (+8% EPS growth) into a −3% EPS decline. Fair value $78–115 → $60–95; entry $65–78 → $58–68. §1–§8 are retained as written, unrevised. §9 records what the print did to them.

Price $74.39 · Market cap $31.19B · 2026-08-05 52wk range $71.47–$160.48 — the stock sits 3 tics off its low and 54% below its high.

⚠️ TIMING — READ FIRST. Zoetis reports Q2 2026 before the open on 2026-08-06 — tomorrow. Consensus: adj EPS $1.85 (+5.1% yoy) on revenue $2.49B (+1.3% yoy). The last print (May 7) took the stock down 21.5% in a day. Any entry decision taken today is a decision to hold a binary event overnight. This report's valuation work survives the print; its tactical conclusion does not.

0 · Knowledge check (before any data was pulled)

Source What it said How it was used
Knowledge/Themes/defensive-income-fields (2026-07-29, live) ZTS surfaced at conviction 7.5 in the July defensive sweep and was rejected by the user on business-model grounds, not price. Note says re-confirm with the user rather than infer. The user has now re-opened ZTS directly, which supersedes the standing constraint for this analysis. The note's conviction of 7.5 is superseded by this report at 6.0 — the sweep did not price the depth of the US companion-animal decline.
Knowledge/Playbook/pitfall-dyt-inverts-when-price-caused-the-yield DYT turns into its loudest buy signal exactly when a business is breaking. Applied below. ZTS is a textbook case; DYT is disqualified as a valuation input here.
Knowledge/Playbook/pitfall-vendor-forward-eps-is-the-wrong-fiscal-year Yahoo's forward P/E silently uses the wrong year. Checked — Yahoo's PE(fwd) 10.07 reconciles to company-guided FY2026 adj EPS. Usable, see §3.
Knowledge/Playbook/pitfall-drug-sales-gross-vs-net-basis List-price scripts ≠ reported net sales. Relevant to third-party derm share commentary; company organic figures used instead.

A portfolio-specific passage was removed from the public build.

1 · Fundamentals Analyst

The headline the screen shows

Metric Value Metric Value
P/E (ttm GAAP) 12.2x P/E (fwd, on guided adj EPS) 10.7x
EV/EBITDA 9.7x FCF yield (mkt cap) 7.3%
Gross margin 71.8% Operating margin 37.6%
Net margin 27.8% ROIC (2025) 23.1%
ROE 68% (flattered — see leverage) Dividend yield 2.74%
Beta 0.73 Net debt / EBITDA 1.72x

On the screen this is an unambiguously high-quality business at a value multiple. That is precisely the configuration analysis_notes.md §0 warns about: great + cheap = value; poor + cheap = value trap.** Everything below is the work of telling those apart.

FCF and the growth stack

2022 2023 2024 2025 TTM
Revenue $8.08B $8.54B $9.26B $9.47B $9.51B
Operating income $2.93B $3.07B $3.39B $3.60B $3.57B
Net income $2.11B $2.34B $2.49B $2.67B $2.64B
OCF $1.91B $2.35B $2.95B $2.90B —
Capex $0.59B $0.73B $0.66B $0.62B —
FCF $1.33B $1.62B $2.30B $2.28B —
Diluted shares 470.4M 462.3M 454.8M 443.8M 422.4M (Q1'26)
Diluted EPS $4.49 $5.07 $5.47 $6.02 $6.03
CAGR (3yr)
Revenue +5.4%
Net income +8.1%
FCF +19.9%
Diluted shares −1.9%/yr
  • FCF/share (2025, on Q1'26 count): $5.40. FCF yield 7.3%.
  • Revenue/share: $21.33 — grew ~7.5%/yr, i.e. ~2pp faster than revenue, entirely from buybacks.
  • ⚠️ FCF has stopped growing. $2.30B → $2.28B. The 19.9% 3yr FCF CAGR is a working-capital recovery artifact off a depressed 2022 base, not a trend. Two flat years is the real signal.
  • The 8.1% net-income CAGR is 5.4pp of revenue and ~2.7pp of nothing but share count. Cross-reference Knowledge/Playbook/pattern-buyback-manufactured-eps-screens-as-growth — ZTS is a mild case, not an egregious one, but strip the buyback and this is a ~5% earner.

🚩 Capital allocation — the sharpest finding in this report

FY2025 use of cash:

Use $ % of FCF
Buybacks $3.23B 142%
Dividends $0.89B 39%
M&A $0.03B 1%
Total returned $4.12B 181% of FCF
Funded by net new debt +$2.50B ($3.85B issued − $1.35B repaid)

Shares outstanding fell 448.5M → 424.9M, i.e. 23.5M net shares retired for $3.23B ≈ $137/share. The stock is $74.39. Zoetis levered its balance sheet — debt $6.74B → $9.24B, equity $4.77B → $3.33B — to repurchase stock at roughly 1.8x today's price, in the year immediately preceding the franchise deterioration management says it did not see coming.

That is roughly $1.5B of shareholder value destroyed versus having simply held the cash, and it is the single strongest piece of evidence for the securities-fraud allegation (§4): management was buying aggressively while, per the complaint, describing the franchise as healthy.

The ROE of 68% is a mathematical artifact of the hollowed equity base, not an operating achievement. Do not quote it as a quality metric.

Balance sheet — leverage is a scar, not a wound

Value Read
Debt $9.24B Up 37% in one year
Cash $2.31B
Net debt $6.93B
Net debt / TTM EBITDA 1.72x Comfortable
Interest coverage (EBIT/interest) ~15.5x Very comfortable
Debt/Assets 59.7% Elevated but serviced easily
Current ratio 3.15 Fine

Verdict: the leverage does not threaten the company. It threatens the narrative — it is proof of a capital-allocation misjudgement, not a solvency issue. The dividend (38% of FCF) is comfortably covered and is not at risk.

Where the revenue actually is (Q1 2026)

Segment Revenue Reported Organic
US $1.1B −8% —
— US companion animal −11%
— US livestock +7%
International $1.1B +17% +10%
— Intl companion animal +15% +7%
— Intl livestock +19% +14%
Companion animal (total) $1.519B −1% −4%
Livestock (total) $0.720B +15% +12%
Total $2.262B +3% flat (0%)

This table is the whole thesis. The headline "+3%" is FX. Organic is zero. And the composition is the wrong way round: the shrinking business (US companion animal, −11%) is the high-margin crown jewel; the growing business (livestock, +12% organic) is the structurally lower-margin, more cyclical, more commoditised half.

Fundamentals scorecard: 5/10. Balance sheet fine, dividend safe, margins intact, cash conversion good — but growth is zero organically, FCF has flatlined for two years, the mix is deteriorating, and the 2025 buyback was a large, debt-funded, badly-timed error.

2 · Moat Analyst

Quantitative base — the moat has not cracked in the numbers yet

2022 2023 2024 2025 Q1'26
Gross margin 69.7% 70.0% 70.6% 71.8% 71.7%
Operating margin 36.3% 35.9% 36.6% 38.0% 36.3%
ROIC (NOPAT/invested capital) 18.8% 21.0% 23.6% 23.1% —

Gross margin in the quarter the franchise fell apart was 71.7% vs 71.9% a year earlier. ROIC rose over the period. By the §2 test — "margin compression = moat erosion" — the moat looks intact.

⚠️ But that is the bear case, not the bull case

This is the most important inference in the report, and it runs against the surface reading:

Zoetis lost 11% of its US companion-animal volume while holding price. The margins have not compressed because the price war has not been fought yet — Zoetis has so far chosen to cede share rather than cut price.

That leaves a fork with no good branch:

  1. Hold price → keep losing volume. Share erosion compounds. Revenue keeps declining, and operating leverage works in reverse on a fixed-cost sales force and manufacturing base.
  2. Cut price to defend share → margins compress. A 71.7% gross margin against generic oclacitinib entering has a very long way to fall. Every 100bp of gross margin is ~$95M of operating income, ~3.5% of net income.

The P&L damage from the competitive event is therefore ahead of the company, not behind it. Management's own language on the Q1 call — "price has played a larger role in the decision process" — says branch 2 is where they are heading.

Adversarial stress-test: "I am Elanco. How do I take this?"

I do not need to speculate — Elanco has already run the play and it is working:

Zoetis franchise Attacker Status
Apoquel (oclacitinib, JAK inhibitor, ~$1.7B) Elanco Zenrelia — once-daily JAK, comparable label, priced below Reached trailing-4Q blockbuster (~$1B) in under 2 years from launch. Core oclacitinib patent lapses ~2026 → generic oclacitinib on top of it.
Cytopoint (lokivetmab, anti-IL-31 mAb, ~$1.0B+) Elanco Befrena (tirnovetmab, anti-IL-31 mAb) US phased launch began 2026-05-18 — the first direct competitor in 8 years in the $1.3B canine derm market.
Simparica Trio (parasiticide) Elanco Credelio Quattro Taking share; cited by management as a driver of the US decline.
Librela (bedinvetmab, canine OA mAb) Self-inflicted FDA "Dear Veterinarian" letter Dec 2024 — seizures, paresis, recumbency, death. Label updated. Q1 2026 sales $101M, −13%.

Verdict on the stress-test: the moat is being taken, on three fronts, simultaneously, by one competitor, and the company is defending on a fourth front against itself. This fails the §2 test as decisively as any name this agency has run.

What survives

The moat is being narrowed, not erased. Genuinely durable pieces:

  • Cytopoint is a biologic. There is no veterinary biosimilar pathway. Befrena is a new branded competitor, not a generic — it splits a duopoly, it does not commoditise the class.
  • Vet-channel distribution and relationships. Real switching friction; slow to erode.
  • Livestock and international. Growing organically at 12% and 7% respectively. Lower margin, but this is a real, diversified, non-US business that the derm war does not touch.
  • Scale in a two-and-a-half-player market. Animal health is not a commodity generics market; regulatory and field-force barriers keep the field small.

Disruption forecast (5–10yr) and evergreen rating

Pet ownership and pet medicalisation are structurally durable demand — but the analysis must separate the field from the company. The field is evergreen; Zoetis's rent within it is not. Zoetis earned monopoly rents on Apoquel for a decade. That specific rent ends around 2026 and is not coming back.

The forward question is whether the pipeline (osteoarthritis programmes, next-gen derm, long-acting formulations) can generate a new rent before the old one fully bleeds out. That is an R&D bet on $698M/yr of R&D (7.4% of revenue) — respectable for animal health, but the company has not yet shown a replacement asset of Apoquel's scale.

Evergreen rating: 5.5/10. A durable business in a durable field, entering a permanent step down in its rate of economic rent. Not a compounder any more; plausibly a good cash cow.

Moat scorecard: 5.5/10 — high current returns, structurally narrowing, with the P&L impact still ahead.

3 · Valuation Analyst

Model applicability

Model Applicable? Why
Graham IV ❌ Reject Computes to $32.80 vs $74.39. Meaningless — BVPS of $7.84 exists only because $3.23B of buybacks hollowed the equity base. Graham's √(22.5·EPS·BVPS) is designed for asset-backed value plays; on a 72%-gross-margin IP business with negative tangible book it produces noise. Per §3, weight ≈ 0.
Dividend Yield Theory ❌ Disqualified See below — this is the exact trap pitfall-dyt-inverts-when-price-caused-the-yield documents.
Bogle expected return ✅ Weight Primary forward-return frame.
FCF yield / reverse DCF ✅ Heaviest weight The right lens for a cash-generative, non-asset-backed franchise with uncertain terminal growth.
Multiple scenarios on guided adj EPS ✅ Weight Guidance is explicit and recent.

⚠️ Why DYT is disqualified here

Input Value
Dividend/share (annualised) ~$2.04
Price $74.39
Current yield 2.74%
5yr average yield 0.95%
Ratio 2.9x
Naive DYT "fair value" ($2.04 ÷ 0.0095) $215

DYT says ZTS is worth $215 — 189% upside. It says this because the denominator halved. Decomposing: the dividend rose from ~$1.30 (2022) to ~$2.04 (~16%/yr, a real and creditable increase), while the price fell from $160 to $74. Both moved, but the price move is ~3x the dividend move in magnitude. DYT cannot see that a permanent re-rating happened; it reads a regime change as a discount. Use the 2.9x ratio as evidence that the market has structurally re-rated the business, never as a valuation output.

Forward EPS reconstruction (per pitfall-vendor-forward-eps-is-the-wrong-fiscal-year)

Yahoo PE(fwd) = 10.07 → implied EPS $7.39. Company FY2026 guidance (revised 2026-05-07) is adj diluted EPS $6.85–$7.00 on revenue $9.68–9.96B. Yahoo is ~6% above the top of guidance — sell-side consensus that has not fully caught the May cut. Use $6.925 (guidance midpoint): true forward P/E = 74.39 ÷ 6.925 = 10.7x. Not the wrong fiscal year here, but optimistic within it. Flagging, not rejecting.

Reverse DCF — what is the market actually pricing?

Input Value
Market cap $31.19B
+ Net debt $6.93B
Enterprise value $38.12B
FCF (2025) $2.28B
EV/FCF 16.7x
Discount rate (beta 0.73, defensive) 9%

Solving a perpetuity: EV/FCF = 1/(r−g) → g ≈ 3.0%.

The market is pricing ~3% perpetual FCF growth — almost exactly the low end of what management guides (2–5% organic). Read plainly: the market is not pricing a collapse. It is pricing "guidance holds, and Zoetis never earns a quality premium again." That is a meaningful finding — it means the de-rating is largely complete, and the remaining risk is guidance not holding, not further multiple compression from here.

Bogle expected return

Component Base Bear Bull
Dividend yield 2.7% 2.7% 2.7%
Earnings growth +3% −5% +6%
P/E change (from 10.7x fwd) +3%/yr (→13x over 5y) −2%/yr +9%/yr (→16x)
Expected annual return ~9% −4% ~18%

Scenario fair value

Scenario FY27 adj EPS Multiple Value Weight
Value trap — derm erosion accelerates, price war compresses margin, US CA keeps declining $5.75 11x $63 25%
Stagnation (base) — guidance roughly holds, no re-rating premium returns $6.90 13x $90 35%
Stabilisation — US CA troughs, livestock/intl carry, multiple normalises to mature-quality $7.10 15x $107 25%
Re-rating — pipeline delivers, share loss halts $7.50 18x $135 15%

Probability-weighted fair value ≈ $95.

🎯 Fair value range: $75 – $110 (central ~$92–95)

Entry zone: $62 – $72 · Trim: 15x fwd

Price $74.39 sits at the very bottom of the fair-value range. It is cheap — but the range is wide because the earnings base itself is the uncertain variable, not the multiple.

Sell-side context — note the stale mean. Yahoo's Target(mean) 110.81 lags badly. The last six actions are all cuts and cluster far lower:

Date Firm Rating PT Prior PT
07-27 UBS Neutral $85 $99
07-22 Morgan Stanley Overweight $99 $115
07-06 HSBC Buy $95 $140
07-01 Barclays Equal-Weight $85 $136
06-30 TD Cowen Buy $104 $150
06-26 Stifel Hold $85 $95
05-27 Argus ↓ Buy → Hold — —
05-08 JP Morgan Overweight $130 $190

Live cluster: $85–$104, which brackets the low-to-middle of my range. Do not quote $110.81.

4 · Sentiment & Intelligence Analyst

The event chain

Date Event
Dec 2024 FDA "Dear Veterinarian" letter on Librela — severe neurological adverse events (seizures, paresis, recumbency, death). Label updated.
Through 2025 Elanco Zenrelia scales to blockbuster; Credelio Quattro takes parasiticide share. Zoetis continues to describe "very strong satisfaction levels" and "record penetration."
FY2025 Zoetis spends $3.23B on buybacks at ~$137/share, debt-funded.
2026-05-07 Q1 miss on both lines. FY26 adj EPS guidance cut $7.00–7.10 → $6.85–7.00. Stock −21.5% in one session, ~$24/share.
2026-05-18 Elanco launches Befrena, first direct Cytopoint competitor in 8 years.
May–Jul 2026 Securities fraud investigations opened (Pomerantz, Levi & Korsinsky, Glancy Prongay, Frank R. Cruz). Class period 2025-01-14 → 2026-05-06. Lead-plaintiff deadline passed 2026-07-27.
Jun–Jul 2026 Eight consecutive price-target cuts. Argus downgrades.
Jul 2026 Michael Burry adds to ZTS around $76 — calls it a "full position" and a "fat pitch."
2026-08-06 Q2 2026 print, pre-market.

Reading it

  • The class action is a real but second-order risk. These are private plaintiff-firm investigations, not an SEC or DOJ action — no evidence of a government probe was found. The financial exposure for a $31B company is manageable. The informational value is higher than the financial value: the complaint's core allegation (that management touted franchise health while share was being taken) is corroborated independently by the buyback timing. Treat management's forward commentary with an explicit discount. Note also that a separate Librela consumer class action was dismissed by a judge — the product-liability tail is thinner than the headlines imply.
  • Burry's position is a data point, not a thesis. He is buying the same statistical cheapness this report finds; his record on "cheap + hated" is mixed and his holding period is short. It does not resolve the earnings-base question. Do not let it substitute for the work.
  • Sentiment is capitulated, not panicked. Eight PT cuts, an Argus downgrade, a 54% drawdown, and the stock is still holding a $71.47 floor. That is distribution finishing, not a falling knife mid-flight. Institutional ownership remains ~100%+ of float; short float 0.05% — there is no short-squeeze story and no crowded-short risk here in either direction.
  • Management credibility is the impaired asset. The CEO's explanation (price-sensitive pet owners, fewer vet visits) is partly true and conveniently macro. The Q1 admission — "share loss is being amplified by a derm market with declining patient volume" — concedes both a market problem and a share problem, which is worse than either alone.

Sentiment scorecard: 4/10. Capitulated positioning is a mild positive; management credibility, litigation overhang and an unbroken cadence of negative revisions are not.

5 · Debate round — the real tension

Valuation vs Moat. These two agents disagree, and the disagreement is the investment case.

Valuation: "The reverse DCF says the market prices 3% perpetual growth against guidance of 2–5%. At 10.7x forward with a 7.3% FCF yield, a 38%-covered 2.7% dividend, 1.7x net leverage and 23% ROIC, the de-rating is done. Everything the Moat analyst describes is in the price."

Moat, rebutting: "You are discounting a guidance number that has already been cut once and that Yahoo's own consensus still sits 6% above. My point is not that erosion is coming — it is that erosion has so far cost Zoetis volume and not one basis point of gross margin. The pricing response has not happened yet. Generic oclacitinib lands on top of Zenrelia and Befrena. Your 3% perpetual growth is not conservative; it assumes the fork in §2 resolves benignly, and neither branch of that fork is benign."

Valuation, conceding partially: "Accepted, and it moves my weighting — that is why the value-trap scenario carries 25% and the bear case is $63, only 15% below spot. But note the asymmetry: for the thesis to lose badly from here, both earnings must fall ~20% and the multiple must break below 10x on a business still generating 23% ROIC and a covered dividend. That is a compound requirement, and it is why I hold a $75–110 range rather than an AVOID."

Manager's resolution — where I come down:

The Moat analyst is right about the direction and the Valuation analyst is right about the price. Both are true simultaneously, and that is the honest description of ZTS.

The user's stated worry is correct on the facts. "Room to grow is genuinely low and getting narrower" is not a feeling — it is measured: organic growth is 0%, US companion animal is −11%, and the highest-margin franchise is losing a three-front war. The user should not be talked out of this.

But the worry is roughly 70% priced. At 10.7x forward and a 7.3% FCF yield, the market has already stopped calling this a compounder. The remaining unpriced risk is specifically the margin leg — the price war that has not yet been fought. That is the one thing to watch.

A portfolio-specific passage was removed from the public build.

7 · Verdict

WATCH — conviction 6.0 / 10

Fair value $75–110 (central ~$92–95) · Entry $62–72 · Trim 15x fwd Do not act before the 2026-08-06 print.

⚠️ SUPERSEDED BY §8. A steelman pass run after this verdict raised conviction to 6.5, fair value to $78–115, and the entry zone to $65–78. §7 is retained as written — the revision is recorded, not edited over. See §8 for the operative verdict.

Your worry is correct, and you should keep it. Zoetis's room to grow is low and is getting narrower — organic growth is zero, the US companion-animal engine is contracting 11%, Apoquel's monopoly rent is ending permanently, and Elanco is attacking three franchises at once while Librela's safety label works against the fourth. Nothing in the data contradicts your read; the data is more damning than the framing.

Where the analysis pushes back is on what that's worth. A business does not need to grow to be a good investment — it needs to be mispriced. At 10.7x guided forward earnings, a 7.3% FCF yield, 23% ROIC, 71.8% gross margins, 1.7x net leverage and a dividend covered 2.6x by free cash flow, the market has already retired ZTS's compounder premium. The reverse DCF prices ~3% perpetual growth against 2–5% guided. This is no longer a great-company-at-a-great-price story; it is a decent-cash-cow-at-a-fair-to-cheap-price story, and those are different investments with different reasons to own them.

Why WATCH rather than ACCUMULATE, despite the price being at the bottom of the range:

  1. Earnings tomorrow. The last print cost 21.5% in a session and the guide has been cut once. Buying today is a coin-flip on a binary, not an investment decision. This alone settles it.
  2. The margin leg is unfought. §2's fork — cede share or cut price — has not resolved. Every quarter that gross margin holds at ~71.7% while volume falls is a quarter of risk deferred, not risk removed.
  3. Management credibility is impaired, so the guidance the valuation rests on carries a discount that the multiple does not currently reflect.
  4. You already rejected this business model six days ago. A 54% drawdown is a reason to re-examine a price, not a reason to reverse a judgement about a business. Nothing found here improves the business — it only confirms the deterioration and shows it is largely priced.

🚩 Risks — named

  1. Margin compression not yet in the P&L (highest) — generic oclacitinib + Zenrelia + Befrena versus a 71.7% gross margin. 100bp of GM ≈ $95M of operating income.
  2. US companion animal decline accelerating past −11% — the highest-margin revenue line.
  3. Guidance risk — FY26 adj EPS $6.85–7.00 has already been cut once; consensus sits above it.
  4. Management credibility / securities class action — class period 2025-01-14 to 2026-05-06.
  5. Value-trap risk — the framework's own §0 warning. Cheap because the rent is ending.
  6. Mix deterioration — growth is coming from lower-margin livestock and FX-flattered international.

🟢 Offsetting

  1. Dividend covered 2.6x by FCF, ~16%/yr growth, ~38% FCF payout — safe, and not a price-driven mirage on the numerator side.
  2. ROIC 23%, gross margin 71.8%, operating margin 37.6% — still an excellent business today.
  3. Leverage comfortable (1.7x net, 15.5x coverage). No refinancing or solvency pressure.
  4. Livestock +12% organic and international +7% organic are real, diversifying, and untouched by the derm war.
  5. Beta 0.73, capitulated positioning, negligible short interest, $71.47 floor holding.
  6. Downside appears contained: the 25%-weighted bear case is $63, ~15% below spot.

What would change the verdict

→ Upgrade toward ACCUMULATE → Downgrade toward AVOID
Q2 shows US companion animal decline decelerating (better than −11%) US companion animal worse than −11%, or a second guidance cut
Gross margin holds ≥71% while volume stabilises Gross margin breaks below 70% — the price war has started
FY26 guidance reaffirmed or raised Buyback continued at scale before the franchise stabilises
Librela US returns to growth An SEC or DOJ inquiry (as distinct from plaintiff-firm probes)
Price into $62–72 with the above intact Free cash flow declines year-over-year in 2026

Immediate action

None today. Re-run after tomorrow's pre-market print. If Q2 shows US companion animal decelerating and gross margin ≥71%, this becomes an ACCUMULATE at 7.0 with an entry zone raised toward $80. If gross margin breaks 70%, the value-trap branch is confirmed and this drops to AVOID regardless of the multiple.

8 · ADDENDUM — The steelman bull case (added 2026-08-05, post-verdict)

Requested explicitly: build the strongest honest argument FOR Zoetis before discarding it. This section is written adversarially against §7. It moved the verdict — conviction 6.0 → 6.5, fair value $75–110 → $78–115, entry $62–72 → $65–78. What follows is the reasoning, and then what it still does not fix.

Pillar 1 — 🎯 The cut guidance still implies +8% adjusted EPS growth

This is the single number I under-weighted, and it is verifiable from the company's own releases:

Figure
FY2025 revenue $9.5B — +2% reported, +6% organic operational
FY2025 adjusted net income $2.8B — +7% organic operational
FY2025 adjusted diluted EPS $6.41
Original FY2026 guide (Feb) Revenue $9.825–10.025B · adj EPS $7.00–7.10 · 3–5% organic
Revised FY2026 guide (May 7) Revenue $9.68–9.96B · adj EPS $6.85–7.00 · 2–5% organic
Implied adj EPS growth, revised guide +6.9% to +9.2% — midpoint +8.0%

The guidance cut that took 21.5% out of the stock in one session still guides to ~8% adjusted EPS growth. The market reacted to the direction of the revision, not its level. At 10.7x forward against +8% guided growth, the PEG is ~1.3 on a business with 71.8% gross margins and 23% ROIC. That is not value-trap pricing; that is pricing for a good year being treated as a bad one.

Pillar 2 — 🎯 The war zone is ~18% of revenue, not the company

The bear narrative ("Elanco is dismantling Zoetis") never sizes the thing being dismantled:

Franchise FY2025 revenue % of $9.47B FY2025 growth
Dermatology (Apoquel + Cytopoint) — the contested franchise $1.74B 18.4% +6% operational
Simparica Trio (US alone >$1B) ~$1.4B+ global ~15% double-digit global
Livestock $2.9B ~31% +12% organic (Q1'26)
International companion animal — — +7% organic (Q1'26)

Two facts follow that the narrative omits. First, the entire global dermatology franchise — the thing Zenrelia, Befrena and generic oclacitinib are attacking — is 18.4% of revenue, and the US portion of it (the actual battlefield) is roughly 11–12%. Even a catastrophic 50% loss of US derm is ~6% of company revenue, spread across several years, against ~6–8% growth in the other ~80%.

Second, and more damning to the bear case: dermatology grew 6% operationally in FY2025. The collapse narrative is one quarter old, not a multi-year trend. §2's competitive analysis is correct about the structure — the monopoly rent is ending — but the bear case reads the Q1 2026 print as though the franchise is already gone. It is not; it is $1.74B and was growing four months before the selloff.

Pillar 3 — 🎯 The 2025 buyback error becomes a 2026+ tailwind at this price

§1 called the $3.23B-at-$137 buyback the sharpest negative in the report, and that stands as a judgement on management. But it is a sunk judgement, and it inverts the arithmetic going forward:

Value
FCF $2.28B
− Dividends $0.89B
= Discretionary cash $1.39B
÷ Market cap $31.19B 4.5% of the company per year, self-funded, no new debt
+ Dividend yield 2.74%
= Total shareholder yield ~7.2%

At $137, $1.39B retired 1.0% of the company. At $74.39 the same dollars retire 1.85x as much stock. The very de-rating that proves management misjudged 2025 is what makes 2026–27 buybacks genuinely accretive. This is already visible: diluted shares fell 448.0M → 422.4M year over year in Q1 2026, −5.7% — and that is where most of the guided +8% adjusted EPS growth comes from, on 2–6% organic net-income growth.

Bogle expected return, recomputed on verified inputs: 2.74% dividend + ~8% EPS growth + 0% multiple change ≈ ~11%/yr with no re-rating whatsoever. The §3 base case assumed a re-rating was needed; it is not.

Pillar 4 — Cytopoint is a biologic, and that matters more than §2 credited

Befrena is a branded competitor, not a generic. There is no veterinary biosimilar pathway, so anti-IL-31 goes from a monopoly to a duopoly — a price and share event, not a commoditisation event. Duopolies in animal health have historically preserved 60–70% gross margins. The Apoquel side does face true generic entry and will commoditise; the Cytopoint side will not. §2 treated these two as one collapsing franchise. They are not the same asset.

Pillar 5 — Librela is free optionality, and one legal risk already resolved

$101M/quarter (~$400M/yr), −13%, and modelled by the market at roughly zero terminal value. But: a judge dismissed the Librela consumer class action, the label has been updated (which resolves rather than perpetuates regulatory uncertainty), and management reports US trends stabilising. Canine osteoarthritis is a large, under-treated category Zoetis created. Any stabilisation is upside not in any model — and the downside is already taken.

Pillar 6 — The downside requires a compound failure

For a permanent loss from $74.39 you need both of: 1. Adjusted EPS to fall ~20% from $6.93 to ~$5.5, and 2. The multiple to break below 10x — on a business with 23% ROIC, 71.8% gross margins, 1.72x net leverage, 15.5x interest coverage and a dividend covered 2.6x by free cash flow.

Either alone is survivable. Both together is the bear case, and it is priced at 25% probability in §3 with a $63 outcome — 15% below spot. Meanwhile a merely dull outcome (guidance holds, no re-rating, buyback continues) compounds at ~11%. That asymmetry is the actual investment case, and it does not require believing anything good about the competitive picture.

Pillar 7 — The reverse DCF bar is low against the non-contested 80%

§3 found the market pricing ~3% perpetual FCF growth. Set against livestock at +12% organic, international companion animal at +7% organic, and a −5.7% annual share count, 3% perpetual is a bar Zoetis clears even if US dermatology goes to zero over a decade. The market is not pricing erosion; it is pricing erosion plus the permanent absence of any offset.

⚖️ What the steelman does not fix

Intellectual honesty requires this to be as prominent as the bull case:

  1. The margin leg is still unfought, and Pillar 1 depends on it. The +8% guided EPS growth assumes gross margin near 71.7%. Every pillar above is downstream of a margin that has not yet been tested by a price war. This is unchanged and remains the single largest risk.
  2. The guide has been cut once and consensus still sits ~6% above it. Pillar 1 leans on guidance from management whose credibility §4 rated impaired. That is a real circularity.
  3. Pillar 3 assumes they keep buying. After the 2025 debacle, the board may — reasonably — throttle repurchases, which removes ~5pp of the ~8% EPS growth.
  4. Pillar 2's "80% is fine" holds only while it holds. Elanco's Credelio Quattro is already attacking Simparica Trio, the largest single product. The war zone can widen.
  5. Nothing here contradicts the user's original worry. Growth is low and is narrowing. The steelman argues the price, never the trajectory.

🔄 Revised verdict after the steelman

WATCH — conviction 6.5 / 10 (raised from 6.0)

Fair value $78–115 (central ~$97) · Entry $65–78 · Trim 15x fwd Price $74.39 is IN the entry zone — but the entry is gated on the 2026-08-06 print.

The steelman changes the characterisation, not the risk. Zoetis is not "a deteriorating business that happens to be cheap" — it is a good business with one large franchise repricing, priced as though the whole company were repricing, and still guiding to 8% EPS growth while it happens. That is a materially different proposition than §7 described, and it earns a half-point of conviction and a place on the watchlist rather than the discard pile.

It does not earn a purchase today. Everything above rests on a gross margin near 71.7% and a guidance number from management with impaired credibility — both of which get tested tomorrow morning. Wait one day, then act on evidence rather than on either narrative.

9 · POST-PRINT — Q2 2026, reported 2026-08-06

Written the morning after §1–§8. This is the gate those sections were explicitly waiting on.

What printed

Q2 2026 vs
Revenue $2.468B $2.474B a year ago — flat reported, −1% organic, missed $2.50B consensus
Adjusted EPS $1.87 BEAT $1.85 consensus ✅
GAAP gross margin 72.7% (−40bp) ✅
US revenue −7% vs −8% in Q1 — marginally less bad

🔴 And the guidance was cut a second time

FY2026 guidance Original (Feb) Revised (May 7) Revised again (Aug 6)
Revenue $9.825–10.025B $9.68–9.96B $9.12–9.32B
Organic revenue growth +3–5% +2–5% −3% to −1% — a DECLINE
Adjusted net income — $2.87–2.95B (+2–6%) $2.57–2.62B (−9% to −5%)
Adjusted diluted EPS $7.00–7.10 $6.85–7.00 $6.15–6.25

Management states the guidance "assumes no near-term market stabilization."

⚠️ The steelman's central pillar is falsified

§8 Pillar 1 was the largest single reason conviction went 6.0 → 6.5:

"The guidance cut that took 21.5% out of the stock still guides to ~8% adjusted EPS growth."

That is now dead. Against FY2025 adjusted EPS of $6.41, the new guide of $6.15–6.25 is −2.5% to −4.1% — an earnings decline, not 8% growth. The pillar survived one day.

Pillar 2 (the war zone is 18% of revenue) and Pillar 3 (buybacks accretive at this price) are intact but no longer sufficient: total organic revenue is now guided negative, which means the ~80% that was supposed to outgrow the contested franchise is no longer doing so.

✅ What the print vindicated — the margin pattern, exactly as written

Knowledge/Playbook/pattern-margin-intact-while-volume-falls-defers-the-damage was written on 2026-08-05 off this very name, predicting that flat margin during share loss means deferred damage rather than an intact moat. The print confirmed it inside 24 hours:

  • Gross margin at 72.7% (−40bp) — the §7 downgrade tripwire (GM <70%) did not fire.
  • Organic revenue went −1% (from 0% in Q1) — volume kept going.
  • Guidance was cut ~11% on adjusted EPS — the P&L catching up, exactly as the note said it would, through the earnings base rather than through the margin line.

Zoetis is still on the "hold price, cede volume" branch. The margin has not broken, and that is no longer reassuring — it is the mechanism.

Scoring the gates I wrote in §7

Gate Result
⬆️ US companion animal decelerating Partial — US total −7% vs −8%. Marginal.
⬆️ Gross margin ≥71% while volume stabilises Half — margin ✅ 72.7%, volume ❌ went −1%
⬆️ FY26 guidance reaffirmed or raised ❌ FAILED — cut again
⬇️ Second guidance cut 🔴 FIRED
⬇️ Gross margin below 70% Did not fire ✅

One downgrade trigger fired; the decisive upgrade trigger failed.

Revised valuation

New FY2026 adjusted EPS midpoint $6.20. At the post-print price of $76.87 (+3.3% on the day — the EPS beat and the held margin outweighed the cut):

True forward P/E = 76.87 ÷ 6.20 = 12.4x — not the 10.4x now showing on vendor screens, which still carries the superseded guidance. Flag per pitfall-vendor-forward-eps-is-the-wrong-fiscal-year.

Scenario FY27 adj EPS Multiple Value Weight
Decline continues — generic oclacitinib lands, no stabilisation $5.60 10x $56 30%
Base — guidance holds, earnings flat, no re-rating $6.20 12x $74 35%
Stabilisation — US CA troughs in 2027 $6.50 14x $91 25%
Re-rating $6.90 16x $110 10%

Probability-weighted ≈ $76.

🎯 Revised: fair value $60–95 (central ~$76) · entry $58–68 · trim 14x fwd

Verdict WATCH — conviction 5.5 (was 6.5)

At $76.87 the stock is now at fair value, not below it. Yesterday at $74.39 it sat at the bottom of a $78–115 range built on +8% guided growth. That range was wrong by one day.

The honest read

The user's original worry is now fully vindicated, and then some. "Room to grow is genuinely low and getting narrower" has become revenue guided to decline outright, with management explicitly assuming no near-term stabilisation. That instinct was correct in July when it was a business-model objection, correct on 2026-08-05 when it was a growth objection, and is now correct as an earnings fact.

The steelman was worth building and was wrong. It argued that the market had over-corrected against a guide implying 8% growth. The guide was the weak link — §8's own stated caveat #2 named exactly this circularity ("Pillar 1 leans on guidance from management whose credibility §4 rated impaired"), and that caveat is what came true. The correct lesson is not "don't steelman" — it is that a steelman resting on management guidance inherits management's credibility, and §4 had already marked that as impaired.

Why WATCH and not AVOID: the business still earns 72.7% gross margins and ~23% ROIC, the dividend is covered ~2.6x by free cash flow and is not at risk, leverage is 1.7x, the EPS beat was real, and at 12.4x on a trough earnings base the price is fair rather than expensive. This is a cash cow being repriced, not a solvency or franchise-collapse story. But there is no margin of safety at $76.87 and no reason to own it before evidence of a trough. Wait for $58–68, or for a print that shows organic revenue back above zero.

Sources